Amgen Brings Suit Against Yet Another Neulasta Biosimilar Maker: Mylan

Generic Line
A A
Amgen leveled new biosimilar patent infringement litigation against Mylan, after the generics manufacturer submitted an FDA application for its version of the company’s Neulasta (pegfilgrastim) therapy earlier this year.

To View This Article:

Login

Subscribe To Generic Line